<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Endocrinol Metab</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Endocrinol Metab</journal-id><journal-id journal-id-type="publisher-id">IJEM</journal-id><journal-title-group><journal-title>Indian Journal of Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2230-8210</issn><issn pub-type="epub">2230-9500</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29285445</article-id><article-id pub-id-type="pmc">5729670</article-id><article-id pub-id-type="publisher-id">IJEM-21-836</article-id><article-id pub-id-type="doi">10.4103/ijem.IJEM_226_17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Comparison of Two Protocols in the Management of Glucocorticoid-induced Hyperglycemia among Hospitalized Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lakhani</surname><given-names>Om J.</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Surender</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Tripathi</surname><given-names>Sudhir</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Desai</surname><given-names>Mitali</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Seth</surname><given-names>Chandani</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib></contrib-group><aff id="aff1">Department of Endocrinology and Metabolism, Sir Ganga Ram Hospital, New Delhi, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Om J. Lakhani, B55 Tagore Nagar, Old Padra Road, Baroda, Vadodara - 390 007, Gujarat, India. E-mail: <email xlink:href="omlakhani@yahoo.com">omlakhani@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2017</year></pub-date><volume>21</volume><issue>6</issue><fpage>836</fpage><lpage>844</lpage><permissions><copyright-statement>Copyright: © 2017 Indian Journal of Endocrinology and Metabolism</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3249" xml_f="3257" txt_i="11" txt_f="19">Context:</offsets></title><p><offsets xml_i="3268" xml_f="3370" txt_i="20" txt_f="122">There is limited literature focusing on the management of glucocorticoid-induced hyperglycemia (GCIH).</offsets></p></sec><sec id="st2"><title><offsets xml_i="3401" xml_f="3406" txt_i="124" txt_f="129">Aims:</offsets></title><p><offsets xml_i="3417" xml_f="3705" txt_i="130" txt_f="418">The primary objective was to compare the mean blood glucose between the experimental group (new protocol) and the control group (standard protocol) in the management of GCIH. The secondary objective was to compare other parameters of glycemic efficacy, variability, and safety parameters.</offsets></p></sec><sec id="st3"><title><offsets xml_i="3736" xml_f="3744" txt_i="420" txt_f="428">Methods:</offsets></title><p><offsets xml_i="3755" xml_f="4329" txt_i="429" txt_f="1003">This was a randomized, open-labeled, parallel arm trial. Adult patients who were given glucocorticoid (minimum dose equivalent to prednisolone 10 mg) in the past 24 h and had 2 h postmeal plasma glucose ≥200 mg/dl were included in the study. Patients randomized to control group received standard basal-bolus insulin. In the experimental group, a “correctional insulin” matching the glycemic profile of the glucocorticoid administered was provided with or without “background” basal-bolus insulin. The parameters of glycemic efficacy, variability, and safety were compared. </offsets><italic><offsets xml_i="4337" xml_f="4338" txt_i="1003" txt_f="1004">P</offsets></italic><offsets xml_i="4347" xml_f="4399" txt_i="1004" txt_f="1053"> &lt; 0.05 was considered statistically significant.</offsets></p></sec><sec id="st4"><title><offsets xml_i="4430" xml_f="4438" txt_i="1055" txt_f="1063">Results:</offsets></title><p><offsets xml_i="4449" xml_f="4720" txt_i="1064" txt_f="1335">Data of 67 patients included in the study were analyzed, of which 33 patients were in the experimental group and 34 patients in the control group. The mean blood glucose in the experimental and the control group was 170.32 ± 33.46 mg/dl and 221.05 ± 49.72, respectively (</offsets><italic><offsets xml_i="4728" xml_f="4729" txt_i="1335" txt_f="1336">P</offsets></italic><offsets xml_i="4738" xml_f="4913" txt_i="1336" txt_f="1511"> = 0.0001). The parameters for glycemic variability were all significantly lower in patients in the experimental group. The hypoglycemia event rate was low in both the groups.</offsets></p></sec><sec id="st5"><title><offsets xml_i="4944" xml_f="4955" txt_i="1513" txt_f="1524">Conclusion:</offsets></title><p><offsets xml_i="4966" xml_f="5106" txt_i="1525" txt_f="1665">When compared to the standard basal-bolus insulin protocol, the new protocol showed lower mean blood glucose and lower glycemic variability.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>Glucocorticoid-induced hyperglycemia</kwd><kwd>steroid-induced diabetes</kwd><kwd>steroid-induced hyperglycemia</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5365" xml_f="5366" txt_i="1674" txt_f="1675">I</offsets><sc><offsets xml_i="5370" xml_f="5381" txt_i="1675" txt_f="1686">NTRODUCTION</offsets></sc></title><p><offsets xml_i="5397" xml_f="5654" txt_i="1687" txt_f="1944">Glucocorticoids are popular therapeutic agents in clinical medicine. One of the major side effects of glucocorticoids is to cause an increase of blood glucose (hyperglycemia). The effect of glucocorticoids on glucose metabolism was first described by Ingle[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="5687" xml_f="5688" txt_i="1944" txt_f="1945">1</offsets></xref><offsets xml_i="5695" xml_f="5705" txt_i="1945" txt_f="1955">] in 1941.</offsets></p><p><offsets xml_i="5712" xml_f="5947" txt_i="1956" txt_f="2191">Management of glucocorticoid-induced hyperglycemia (GCIH) among hospitalized patients is a challenge. A study revealed that 64% of indoor patients who received glucocorticoids equivalent to prednisolone ≥40 mg developed hyperglycemia.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="5980" xml_f="5981" txt_i="2191" txt_f="2192">2</offsets></xref><offsets xml_i="5988" xml_f="6231" txt_i="2192" txt_f="2435">] Hyperglycemia induced by glucocorticoids has an impact on mortality and morbidity. Studies in patients with hematological malignancies who develop GCIH have shown increased hospital stay, mortality, sepsis, and shorter periods of remission.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6264" xml_f="6265" txt_i="2435" txt_f="2436">3</offsets></xref><offsets xml_i="6272" xml_f="6273" txt_i="2436" txt_f="2437">]</offsets></p><p><offsets xml_i="6280" xml_f="6776" txt_i="2438" txt_f="2934">Based on our review of literature and understanding of the pharmacokinetics and pharmacodynamics of glucocorticoids, we developed a new protocol for the management of GCIH in hospitalized patients. The new protocol included the use of a “correctional insulin” which matches the glycemic profile of the glucocorticoid administered with or without “background” basal-bolus insulin. The dose of correctional insulin was based on the dose of the administered glucocorticoid and weight of the patient.</offsets></p><p><offsets xml_i="6783" xml_f="7009" txt_i="2935" txt_f="3161">The primary aim of the study was to compare the mean blood glucose between the experimental group (new protocol) and the control group (standard basal-bolus insulin protocol) in the management of GCIH in hospitalized patients.</offsets></p><p><offsets xml_i="7016" xml_f="7173" txt_i="3162" txt_f="3319">The secondary objective was to compare other parameters of glycemic efficacy between the two groups, glycemic variability. and safety between the two groups.</offsets></p></sec><sec sec-type="methods" id="sec1-2"><title><offsets xml_i="7226" xml_f="7227" txt_i="3321" txt_f="3322">M</offsets><sc><offsets xml_i="7231" xml_f="7237" txt_i="3322" txt_f="3328">ETHODS</offsets></sc></title><p><offsets xml_i="7253" xml_f="7536" txt_i="3329" txt_f="3612">This study was conducted at a single tertiary care institution in New Delhi. This was a randomized, open-labeled, parallel arm trial. Permission for the study was granted by the Institutional Ethics Committee on August 4, 2014. The study was conducted from August 2014 to April 2016.</offsets></p><p><offsets xml_i="7543" xml_f="7603" txt_i="3613" txt_f="3673">We used the data from the pilot study conducted by Seggelke </offsets><italic><offsets xml_i="7611" xml_f="7616" txt_i="3673" txt_f="3678">et al</offsets></italic><offsets xml_i="7625" xml_f="7627" txt_i="3678" txt_f="3680">.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="7660" xml_f="7661" txt_i="3680" txt_f="3681">4</offsets></xref><offsets xml_i="7668" xml_f="7948" txt_i="3681" txt_f="3961">] for calculating our sample size. The calculated sample size was 23 for each group (total of 46). However, to improve the power of the study, we had decided to enroll 92 patients (double the calculated sample size). This gave our study a power of 99% with an alpha error of 0.05.</offsets></p><p><offsets xml_i="7955" xml_f="8455" txt_i="3962" txt_f="4462">Patients screened for eligibility to be included in the study were nonpregnant patients of ages 18 years and above, with or without diabetes mellitus (Type 1, Type 2, or other forms of diabetes mellitus), who were admitted to the nonintensive care unit of our hospital from August 2014 to April 2016. A screening was conducted to find the patients who were given systemic glucocorticoid (oral or parenteral) for any indication (minimum dose equivalent to prednisolone dose of 10 mg) in the past 24 h.</offsets></p><p><offsets xml_i="8462" xml_f="8763" txt_i="4463" txt_f="4764">Plasma glucose was checked 2 h after lunch and 2 h after dinner within 24–48 h of the patients receiving the glucocorticoid. The patients included in the study were those who had 2 h postlunch and/or 2 h postdinner plasma glucose ≥200 mg/dl. The detailed inclusion and exclusion criteria are given in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="8795" xml_f="8802" txt_i="4764" txt_f="4771">Table 1</offsets></xref><offsets xml_i="8809" xml_f="8810" txt_i="4771" txt_f="4772">.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="8858" xml_f="8865" txt_i="4773" txt_f="4780">Table 1</offsets></label><caption><p><offsets xml_i="8885" xml_f="8931" txt_i="4780" txt_f="4826">Inclusion and exclusion criteria for the study</offsets></p></caption><graphic xlink:href="IJEM-21-836-g001"></graphic></table-wrap><sec id="sec2-1"><title><offsets xml_i="9031" xml_f="9046" txt_i="4827" txt_f="4842">Study procedure</offsets></title><p><offsets xml_i="9057" xml_f="9388" txt_i="4843" txt_f="5174">Patients were recruited in the study once they signed the consent form. On recruitment, the patients were randomized to either the control group or the experimental group using computer-generated random numbers. Baseline demographic and clinical data were collected from the hospital records for all patients included in the study.</offsets></p><p><offsets xml_i="9395" xml_f="9655" txt_i="5175" txt_f="5435">All oral antidiabetics, premixed insulin, and noninsulin injectable antidiabetics were stopped in both the groups. Patient already taking basal-bolus insulin at home was allowed to continue the same with necessary adjustments as per the group allotted to them.</offsets></p><p><offsets xml_i="9662" xml_f="9824" txt_i="5436" txt_f="5598">All patients received fixed carbohydrate meals three times a day. Unless there was a specific reason, all patients received their meals at fixed times of the day.</offsets></p><p><offsets xml_i="9831" xml_f="10295" txt_i="5599" txt_f="6063">In all cases, capillary blood glucose (CBG) monitoring was carried out four times a day (three times before meals and at bedtime) using a glucometer. Our hospital uses glucometers from the same manufacturer in all the wards and it is regularly calibrated. All glucometer readings were informed to a member of the endocrinology team in real-time and also noted on the nursing charts. Data were obtained from these nursing charts by study investigators the next day.</offsets></p><p><offsets xml_i="10302" xml_f="10893" txt_i="6064" txt_f="6649">Adjustments were made to insulin regimen depending on the protocol assigned to the patient. Additional CBG readings were taken if the patient complained of symptoms suggestive of hypoglycemia and/or the treating endocrinologist ordered additional readings. If the additional blood glucose reading was suggestive of hypoglycemia (blood glucose &lt;70 mg/dl) or severe hyperglycemia (blood glucose &gt;300 mg/dl), the readings were counted in the event rate of hypoglycemia or severe hyperglycemia, respectively; however, the readings were not taken to calculate the other glycemic parameters.</offsets></p><p><offsets xml_i="10900" xml_f="11186" txt_i="6650" txt_f="6933">Any cases of hypoglycemia (blood glucose &lt;70 mg/dl) were managed according to the existing protocol developed by the endocrinology department. If patient was given any correction for hypoglycemia, then the blood glucose readings for the rest of the day were discarded from the study.</offsets></p><p><offsets xml_i="11193" xml_f="11671" txt_i="6934" txt_f="7400">If the patient developed any episode of blood glucose &gt;250 mg/dl, urinary ketones were checked. If any patient developed diabetic ketoacidosis (defined as blood glucose &gt;250 mg/dl, urine ketone positive, pH &lt;7.3, and serum bicarbonate &lt;18 mEq/l), it was appropriately managed and that patient was excluded from the study. However, if the patient did not have diabetic ketoacidosis, the hyperglycemic excursion was managed as per the protocol assigned to the patient.</offsets></p><p><offsets xml_i="11678" xml_f="12045" txt_i="7401" txt_f="7765">If the patient developed blood glucose &gt;400 mg/dl without ketoacidosis, the patient was given additional corrective dose of insulin as per the hospital protocol, irrespective of the group he was randomized to, and blood glucose readings for the rest of the day were discarded from the study. The event was however counted in the even rate for severe hyperglycemia.</offsets></p></sec><sec id="sec2-2"><title><offsets xml_i="12079" xml_f="12092" txt_i="7767" txt_f="7780">Control group</offsets></title><p><offsets xml_i="12103" xml_f="12234" txt_i="7781" txt_f="7912">Treatment protocol for the control group was standard basal-bolus insulin regimen as detailed in the Endocrine Society guidelines.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="12267" xml_f="12268" txt_i="7912" txt_f="7913">5</offsets></xref><offsets xml_i="12275" xml_f="12276" txt_i="7913" txt_f="7914">]</offsets></p></sec><sec id="sec2-3"><title><offsets xml_i="12310" xml_f="12328" txt_i="7916" txt_f="7934">Experimental group</offsets></title><p><offsets xml_i="12339" xml_f="12649" txt_i="7935" txt_f="8245">Patients randomized to the experimental group were managed according to the new protocol developed by us. The basis of this protocol is that giving an additional “correctional insulin” which matches the glycemic profile of the glucocorticoid administered would negate the glycemic effect of the glucocorticoid.</offsets></p><p><offsets xml_i="12656" xml_f="12922" txt_i="8246" txt_f="8512">The first step in the experimental group was to classify the patient according to whether they had established diabetes mellitus or developed hyperglycemia secondary to administration of glucocorticoids. They were divided into two groups, namely Group 1 and Group 2.</offsets></p><p><offsets xml_i="12929" xml_f="13280" txt_i="8513" txt_f="8864">Group 1 was the group of patients having established diabetes mellitus. Patients included in this group were those who fulfilled any of the following criteria: (a) patient having a history of diabetes mellitus as per their medical records, (b) patients on oral/injectable antidiabetic medications or insulin, and (c) glycated hemoglobin (HbA1c) ≥6.5%.</offsets></p><p><offsets xml_i="13287" xml_f="13539" txt_i="8865" txt_f="9117">The second group patients (Group 2) were those who did not have established diabetes mellitus but developed hyperglycemia after administration of glucocorticoids. Patient who did not fulfill any of the criteria enlist above were categorized as Group 2.</offsets></p><p><offsets xml_i="13546" xml_f="13864" txt_i="9118" txt_f="9436">The heart of our study was the administration of a “correctional insulin” to be given along with the glucocorticoid depending on the dose and type of glucocorticoid administered. The insulin given as correctional insulin would match the glycemic profile of the glucocorticoid administered. This is presented in Tables </offsets><xref ref-type="table" rid="T2"><offsets xml_i="13896" xml_f="13897" txt_i="9436" txt_f="9437">2</offsets></xref><offsets xml_i="13904" xml_f="13909" txt_i="9437" txt_f="9442"> and </offsets><xref ref-type="table" rid="T3"><offsets xml_i="13941" xml_f="13942" txt_i="9442" txt_f="9443">3</offsets></xref><offsets xml_i="13949" xml_f="13950" txt_i="9443" txt_f="9444">.</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="13998" xml_f="14005" txt_i="9445" txt_f="9452">Table 2</offsets></label><caption><p><offsets xml_i="14025" xml_f="14133" txt_i="9452" txt_f="9560">Type of correctional insulin to be used along with the glucocorticoid administered in the experimental group</offsets></p></caption><graphic xlink:href="IJEM-21-836-g002"></graphic></table-wrap><table-wrap id="T3" position="float"><label><offsets xml_i="14253" xml_f="14260" txt_i="9561" txt_f="9568">Table 3</offsets></label><caption><p><offsets xml_i="14280" xml_f="14386" txt_i="9568" txt_f="9674">Dose of the correctional insulin given along with the respective glucocorticoids in the experimental group</offsets></p></caption><graphic xlink:href="IJEM-21-836-g003"></graphic></table-wrap><p><offsets xml_i="14465" xml_f="14743" txt_i="9675" txt_f="9953">Apart from the correctional dose of insulin, patients with established diabetes mellitus (Group 1) were given additional background basal-bolus insulin while those in Group 2 were not given any additional background insulin. The indication for background insulin is detailed in </offsets><xref ref-type="table" rid="T4"><offsets xml_i="14775" xml_f="14782" txt_i="9953" txt_f="9960">Table 4</offsets></xref><offsets xml_i="14789" xml_f="14790" txt_i="9960" txt_f="9961">.</offsets></p><table-wrap id="T4" position="float"><label><offsets xml_i="14838" xml_f="14845" txt_i="9962" txt_f="9969">Table 4</offsets></label><caption><p><offsets xml_i="14865" xml_f="14915" txt_i="9969" txt_f="10019">Summary of protocol used in the experimental group</offsets></p></caption><graphic xlink:href="IJEM-21-836-g004"></graphic></table-wrap><p><offsets xml_i="14994" xml_f="15184" txt_i="10020" txt_f="10210">Those patients who were assigned to receive additional background insulin (Group 1) were given basal-bolus insulin. The total starting dose of insulin was same as that in the control group [</offsets><xref ref-type="table" rid="T5"><offsets xml_i="15216" xml_f="15223" txt_i="10210" txt_f="10217">Table 5</offsets></xref><offsets xml_i="15230" xml_f="15484" txt_i="10217" txt_f="10471">]. The total starting dose was divided as 50% basal and 50% bolus insulin. Basal insulin used was insulin glargine, and short-acting bolus insulin used was insulin lispro. The basal insulin glargine was given at bedtime and the dose titrated as shown in </offsets><xref ref-type="table" rid="T6"><offsets xml_i="15516" xml_f="15523" txt_i="10471" txt_f="10478">Table 6</offsets></xref><offsets xml_i="15530" xml_f="15531" txt_i="10478" txt_f="10479">.</offsets></p><table-wrap id="T5" position="float"><label><offsets xml_i="15579" xml_f="15586" txt_i="10480" txt_f="10487">Table 5</offsets></label><caption><p><offsets xml_i="15606" xml_f="15687" txt_i="10487" txt_f="10568">Total starting dose of insulin for patients in the experimental and control group</offsets></p></caption><graphic xlink:href="IJEM-21-836-g005"></graphic></table-wrap><table-wrap id="T6" position="float"><label><offsets xml_i="15807" xml_f="15814" txt_i="10569" txt_f="10576">Table 6</offsets></label><caption><p><offsets xml_i="15834" xml_f="15905" txt_i="10576" txt_f="10647">Adjustment of basal insulin dose in the experimental and control groups</offsets></p></caption><graphic xlink:href="IJEM-21-836-g006"></graphic></table-wrap><p><offsets xml_i="15984" xml_f="16309" txt_i="10648" txt_f="10973">Bolus insulin was administered 15 min before each meal. A supplemental dose of short-acting insulin lispro was given depending on premeal CBG readings. The premeal blood glucose readings were informed to the treating endocrinologist on the phone and the supplemental dose of insulin as administered as per the scale shown in </offsets><xref ref-type="table" rid="T7a"><offsets xml_i="16342" xml_f="16350" txt_i="10973" txt_f="10981">Table 7a</offsets></xref><offsets xml_i="16357" xml_f="16482" txt_i="10981" txt_f="11106">. This scale is based on the “usual” column of the supplemental insulin scale described in the Endocrine Society guidelines.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="16515" xml_f="16516" txt_i="11106" txt_f="11107">5</offsets></xref><offsets xml_i="16523" xml_f="16742" txt_i="11107" txt_f="11326">] The patients in the control group were given “higher” dose of supplemental correctional insulin based on the “insulin-resistant” column of the supplemental insulin scale described in the Endocrine Society guidelines [</offsets><xref ref-type="table" rid="T7b"><offsets xml_i="16775" xml_f="16783" txt_i="11326" txt_f="11334">Table 7b</offsets></xref><offsets xml_i="16790" xml_f="16912" txt_i="11334" txt_f="11456">]. This was an additional dose over and above the scheduled bolus dose of insulin in both control and experimental groups.</offsets></p><table-wrap id="T7a" position="float"><label><offsets xml_i="16961" xml_f="16969" txt_i="11457" txt_f="11465">Table 7a</offsets></label><caption><p><offsets xml_i="16989" xml_f="17051" txt_i="11465" txt_f="11527">Supplemental dose of premeal insulin for experimental protocol</offsets></p></caption><graphic xlink:href="IJEM-21-836-g007"></graphic></table-wrap><table-wrap id="T7b" position="float"><label><offsets xml_i="17172" xml_f="17180" txt_i="11528" txt_f="11536">Table 7b</offsets></label><caption><p><offsets xml_i="17200" xml_f="17257" txt_i="11536" txt_f="11593">Supplemental dose of premeal insulin in the control group</offsets></p></caption><graphic xlink:href="IJEM-21-836-g008"></graphic></table-wrap><p><offsets xml_i="17336" xml_f="17681" txt_i="11594" txt_f="11939">Those who were basal-bolus insulin before admission were allowed to continue the same in the experimental group. The basal insulin and bolus insulin were changed to glargine and lispro, respectively, for the purpose of the study. In addition, “correctional insulin” was administered depending on the dose and type of glucocorticoid administered.</offsets></p><p><offsets xml_i="17688" xml_f="17909" txt_i="11940" txt_f="12161">Patients were followed up for the entire length of hospital stay till discharge. The discharge advice for the diabetes management was determined by the treating endocrinologist in consultation with the treating physician.</offsets></p></sec><sec id="sec2-4"><title><offsets xml_i="17943" xml_f="17981" txt_i="12163" txt_f="12201">Measurement of the glycemic parameters</offsets></title><p><offsets xml_i="17992" xml_f="18103" txt_i="12202" txt_f="12313">CBG monitoring was carried out four times a day (fasting, prelunch, predinner, and bedtime) using a glucometer.</offsets></p><p><offsets xml_i="18110" xml_f="18460" txt_i="12314" txt_f="12664">Data from day 1 of randomization were not used to calculate any of the parameters mentioned below because the patient would be still in a titration phase on day 1. Hence, the blood glucose readings taken to calculate the mean blood glucose and all the other parameters excluded the readings from day 1 in both the control and the experimental groups.</offsets></p><sec id="sec3-1"><title><offsets xml_i="18488" xml_f="18539" txt_i="12665" txt_f="12716">Comparison of other parameters of glycemic efficacy</offsets></title><p><offsets xml_i="18550" xml_f="18737" txt_i="12717" txt_f="12904">Apart from the mean blood glucose, the mean fasting blood glucose, mean prelunch, mean predinner, mean bedtime, and mean premeal blood glucose were calculated from the blood glucose data.</offsets></p><p><offsets xml_i="18744" xml_f="19001" txt_i="12905" txt_f="13162">The percentages of blood glucose readings in the target range were calculated. The target range for fasting, prelunch, predinner, and bedtime blood glucose values was determined as 100–140 mg/dl. The target range for bedtime blood glucose was 140–180 mg/dl.</offsets></p></sec><sec id="sec3-2"><title><offsets xml_i="19035" xml_f="19089" txt_i="13164" txt_f="13218">Comparison of other parameters of glycemic variability</offsets></title><p><offsets xml_i="19100" xml_f="19446" txt_i="13219" txt_f="13565">We compared the parameters for glycemic variability between the two groups. Standard deviation (SD) of blood glucose was calculated using standard mathematical equation. Mean daily SD is the mean of the SD of blood glucose of each individual day. Mean daily delta blood glucose is the mean of the daily maximum minus daily minimum blood glucose.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="19479" xml_f="19480" txt_i="13565" txt_f="13566">6</offsets></xref><offsets xml_i="19487" xml_f="19728" txt_i="13566" txt_f="13807">] Mean amplitude of glycemic excursion (MAGE) is the mean of the absolute values of the increases or decreases of blood glucose from the nadir or the peak (the increase or decrease should be more than one SD of that day to qualify). Service </offsets><italic><offsets xml_i="19736" xml_f="19741" txt_i="13807" txt_f="13812">et al</offsets></italic><offsets xml_i="19750" xml_f="19752" txt_i="13812" txt_f="13814">.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="19785" xml_f="19786" txt_i="13814" txt_f="13815">7</offsets></xref><offsets xml_i="19793" xml_f="19873" txt_i="13815" txt_f="13895">] have described in detail the procedure for calculating MAGE from CBG readings.</offsets></p></sec><sec id="sec3-3"><title><offsets xml_i="19907" xml_f="19941" txt_i="13897" txt_f="13931">Comparison of parameters of safety</offsets></title><p><offsets xml_i="19952" xml_f="20227" txt_i="13932" txt_f="14201">Percentage of readings showing hypoglycemia and severe hyperglycemia were calculated for assessment of the safety of the two protocols. Hypoglycemia was defined as blood glucose value &lt;70 mg/dl, and severe hyperglycemia was defined as blood glucose value of &gt;300 mg/dl.</offsets></p></sec></sec><sec id="sec2-5"><title><offsets xml_i="20267" xml_f="20285" txt_i="14204" txt_f="14222">Laboratory methods</offsets></title><p><offsets xml_i="20296" xml_f="20567" txt_i="14223" txt_f="14494">Plasma glucose concentration was measured with glucose oxidase method on Beckman Coulter Unicel DXC-800 analyzer. HbA1c was measured using ion-exchange high-performance liquid chromatography (Bio-Rad D-10 analyzer). The reference range of the test was from 3.8% to 18.5%.</offsets></p><p><offsets xml_i="20574" xml_f="20581" txt_i="14495" txt_f="14502">Contour</offsets><sup><offsets xml_i="20586" xml_f="20587" txt_i="14502" txt_f="14503">®</offsets></sup><offsets xml_i="20593" xml_f="20881" txt_i="14503" txt_f="14791"> Next glucometer was used for CBG measurements (manufactured by Bayer HealthCare LLC). Fingertips were used for CBG sample using standard lancing device provided by the manufacturer. The test strips used flavin adenine dinucleotide-glucose dehydrogenase method for blood glucose testing.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="20914" xml_f="20915" txt_i="14791" txt_f="14792">8</offsets></xref><offsets xml_i="20922" xml_f="21061" txt_i="14792" txt_f="14931">] The results of the glucometer are referenced to plasma/serum blood glucose values. The measuring range of the glucometer is 10–600 mg/dl.</offsets></p></sec><sec id="sec2-6"><title><offsets xml_i="21095" xml_f="21115" txt_i="14933" txt_f="14953">Statistical analysis</offsets></title><p><offsets xml_i="21126" xml_f="21265" txt_i="14954" txt_f="15093">All parametric variables were expressed as mean ± SD, and nonparametric variables were expressed as median ± interquartile range. Unpaired </offsets><italic><offsets xml_i="21273" xml_f="21274" txt_i="15093" txt_f="15094">t</offsets></italic><offsets xml_i="21283" xml_f="21461" txt_i="15094" txt_f="15272">-test was used to compare the means of parametric data and Mann–Whitney U-test was used to compare nonparametric data. Categorical variables were compared using Chi-square test. </offsets><italic><offsets xml_i="21469" xml_f="21470" txt_i="15272" txt_f="15273">P</offsets></italic><offsets xml_i="21479" xml_f="21647" txt_i="15273" txt_f="15438"> &lt;0.05 was considered statistically significant. IBM SPSS Statistics version 20.0 software (IBM Co., Armonk, NY, USA) was used for carrying out statistical analysis.</offsets></p></sec></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="21706" xml_f="21707" txt_i="15441" txt_f="15442">R</offsets><sc><offsets xml_i="21711" xml_f="21717" txt_i="15442" txt_f="15448">ESULTS</offsets></sc></title><sec id="sec2-7"><title><offsets xml_i="21754" xml_f="21789" txt_i="15449" txt_f="15484">Participant flow and patient number</offsets></title><p><offsets xml_i="21800" xml_f="22578" txt_i="15485" txt_f="16263">A total of 3110 adult, nonpregnant patients admitted to the nonintensive care unit of our hospital from August 2014 to April 2016 were screened for eligibility. Of these, 234 patients received glucocorticoids for any indication with dose equivalent to prednisolone 10 mg or above. Plasma glucose was checked 2 h after lunch and 2 h after dinner within 24–48 h of the patient receiving the glucocorticoid. A total of 103 patients developed 2 h postlunch and/or 2 h postdinner plasma glucose ≥200 mg/dl. Five of these patients either declined or were unable to give consent. A total of six patients were excluded because they met one or more of the exclusion criteria. Two of these refused to take insulin and four of the patients were given enteral or total parenteral nutrition.</offsets></p><p><offsets xml_i="22585" xml_f="22890" txt_i="16264" txt_f="16569">The remaining 92 patients were randomized to either experimental or control group. All patients received the allocated intervention. On follow-up during the hospital stay, 10 patients in the experimental group and 11 patients in the control group were excluded. The reasons for exclusions are detailed in </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="22920" xml_f="22928" txt_i="16569" txt_f="16577">Figure 1</offsets></xref><offsets xml_i="22935" xml_f="22936" txt_i="16577" txt_f="16578">.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="22977" xml_f="22985" txt_i="16579" txt_f="16587">Figure 1</offsets></label><caption><p><offsets xml_i="23005" xml_f="23066" txt_i="16587" txt_f="16648">Participant flow diagram (based on consort 2010 flow diagram)</offsets></p></caption><graphic xlink:href="IJEM-21-836-g009"></graphic></fig><p><offsets xml_i="23138" xml_f="23807" txt_i="16649" txt_f="17318">As per our study procedure, CBG readings from day 1 of randomization were excluded in the final analysis. For those patients who developed hypoglycemia which was corrected or severe hyperglycemia which was corrected, the CBG data for the rest of the day were excluded from the analysis. If after exclusion of these CBG readings, the remaining number of CBG was ≤8, the patient was excluded from analysis. There were three such patients in the experimental group and one such patient in the control group who was excluded from the final analysis. After all the exclusions, data of 34 patients in the control group and 33 patients in the experimental group were analyzed.</offsets></p><p><offsets xml_i="23814" xml_f="23994" txt_i="17319" txt_f="17499">The mean age of the patients in the study was 54 years. 71% of the study patients recruited were males. The mean weight and body mass index of the patients were 71 kg and 25.6 kg/m</offsets><sup><offsets xml_i="23999" xml_f="24000" txt_i="17499" txt_f="17500">2</offsets></sup><offsets xml_i="24006" xml_f="24183" txt_i="17500" txt_f="17677">, respectively. The mean HbA1c was 6.8% and mean creatinine was 1.2 mg/dl. There was no statistically significant difference in the baseline demographic data of the two groups [</offsets><xref ref-type="table" rid="T8"><offsets xml_i="24215" xml_f="24222" txt_i="17677" txt_f="17684">Table 8</offsets></xref><offsets xml_i="24229" xml_f="24231" txt_i="17684" txt_f="17686">].</offsets></p><table-wrap id="T8" position="float"><label><offsets xml_i="24279" xml_f="24286" txt_i="17687" txt_f="17694">Table 8</offsets></label><caption><p><offsets xml_i="24306" xml_f="24373" txt_i="17694" txt_f="17761">Baseline demographic and clinical characteristics of the two groups</offsets></p></caption><graphic xlink:href="IJEM-21-836-g010"></graphic></table-wrap><p><offsets xml_i="24452" xml_f="24939" txt_i="17762" txt_f="18249">Patients with established diabetes mellitus who received glucocorticoids as well as nondiabetics who developed hyperglycemia after administration of glucocorticoids were included in the study. Forty-two percent of patients in the experimental group and 64% patients in the control group had preexisting diabetes mellitus. Although the proportion of patients with preexisting diabetes in the experimental and control group was different, the difference was not statistically significant (</offsets><italic><offsets xml_i="24947" xml_f="24948" txt_i="18249" txt_f="18250">P</offsets></italic><offsets xml_i="24957" xml_f="24966" txt_i="18250" txt_f="18259"> = 0.08).</offsets></p><p><offsets xml_i="24973" xml_f="25420" txt_i="18260" txt_f="18707">Oral prednisolone was the most frequently used glucocorticoid in both the groups. Besides this, oral or parenteral hydrocortisone, methylprednisolone, and dexamethasone were also used. The difference in the proportions of various glucocorticoids used in the two groups was different. However, the proportion of patients receiving prednisolone versus glucocorticoid other than prednisolone was not statistically significant between the two groups (</offsets><italic><offsets xml_i="25428" xml_f="25429" txt_i="18707" txt_f="18708">P</offsets></italic><offsets xml_i="25438" xml_f="25447" txt_i="18708" txt_f="18717"> = 0.22).</offsets></p><p><offsets xml_i="25454" xml_f="25811" txt_i="18718" txt_f="19075">There was no significant difference among the doses of the prednisolone between the two groups. The dose of all glucocorticoids was converted to the equivalent dose of prednisolone and compared between the two groups. The dose all glucocorticoid when converted to the equivalent dose of prednisolone showed no significant difference between the two groups [</offsets><xref ref-type="table" rid="T9"><offsets xml_i="25843" xml_f="25850" txt_i="19075" txt_f="19082">Table 9</offsets></xref><offsets xml_i="25857" xml_f="25986" txt_i="19082" txt_f="19211">]. Oral prednisolone, when it was used, was most frequently prescribed in the morning time (between 8 and 9 a.m.) in both groups.</offsets></p><table-wrap id="T9" position="float"><label><offsets xml_i="26034" xml_f="26041" txt_i="19212" txt_f="19219">Table 9</offsets></label><caption><p><offsets xml_i="26061" xml_f="26111" txt_i="19219" txt_f="19269">Mean dose of glucocorticoid used in the two groups</offsets></p></caption><graphic xlink:href="IJEM-21-836-g011"></graphic></table-wrap></sec><sec id="sec2-8"><title><offsets xml_i="26217" xml_f="26302" txt_i="19271" txt_f="19356">Comparison of parameters of glycemic efficacy between experimental and control groups</offsets></title><p><offsets xml_i="26313" xml_f="26577" txt_i="19357" txt_f="19621">The glycemic parameters were compared between experimental and control groups. The mean blood glucose and all the other blood glucose readings including fasting, prelunch, predinner, bedtime, and premeal overall were all significantly lower in experimental group [</offsets><xref ref-type="table" rid="T10"><offsets xml_i="26610" xml_f="26618" txt_i="19621" txt_f="19629">Table 10</offsets></xref><offsets xml_i="26625" xml_f="26630" txt_i="19629" txt_f="19634"> and </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="26660" xml_f="26668" txt_i="19634" txt_f="19642">Figure 2</offsets></xref><offsets xml_i="26675" xml_f="26878" txt_i="19642" txt_f="19845">]. The mean blood glucose in the experimental group was 170.32 mg/dl while that in the control group was 214.99 mg/dl. The experimental group had better glycemic control as compared to the control group.</offsets></p><fig id="F2" position="float"><label><offsets xml_i="26919" xml_f="26927" txt_i="19846" txt_f="19854">Figure 2</offsets></label><caption><p><offsets xml_i="26947" xml_f="27092" txt_i="19854" txt_f="19999">Difference in mean blood glucose readings at various time points in the experimental and the control groups (y axis shows blood glucose in mg/dl)</offsets></p></caption><graphic xlink:href="IJEM-21-836-g012"></graphic></fig><table-wrap id="T10" position="float"><label><offsets xml_i="27206" xml_f="27214" txt_i="20000" txt_f="20008">Table 10</offsets></label><caption><p><offsets xml_i="27234" xml_f="27310" txt_i="20008" txt_f="20084">Comparison of glycemic parameters in experimental group versus control group</offsets></p></caption><graphic xlink:href="IJEM-21-836-g013"></graphic></table-wrap><p><offsets xml_i="27389" xml_f="27621" txt_i="20085" txt_f="20317">The parameters which assessed the blood glucose in target ranges were higher in the experimental group. However, except for the percentage of premeal blood glucose in target range, the differences were not statistically significant.</offsets></p><p><offsets xml_i="27628" xml_f="27838" txt_i="20318" txt_f="20528">The parameters for glycemic variability (SD of blood glucose, SD of premeal blood glucose, mean delta blood glucose, mean daily SD, and MAGE) were all significantly lower in patients in the experimental group [</offsets><xref ref-type="table" rid="T11"><offsets xml_i="27871" xml_f="27879" txt_i="20528" txt_f="20536">Table 11</offsets></xref><offsets xml_i="27886" xml_f="27976" txt_i="20536" txt_f="20626">]. The experimental group had lower glycemic variability as compared to the control group.</offsets></p><table-wrap id="T11" position="float"><label><offsets xml_i="28025" xml_f="28033" txt_i="20627" txt_f="20635">Table 11</offsets></label><caption><p><offsets xml_i="28053" xml_f="28141" txt_i="20635" txt_f="20723">Comparison of glycemic variability parameters in experimental group versus control group</offsets></p></caption><graphic xlink:href="IJEM-21-836-g014"></graphic></table-wrap><p><offsets xml_i="28220" xml_f="28331" txt_i="20724" txt_f="20832">The hypoglycemia event rates (hypoglycemia defined by blood glucose &lt;70 mg/dl) were low in both the groups [</offsets><xref ref-type="table" rid="T12"><offsets xml_i="28364" xml_f="28372" txt_i="20832" txt_f="20840">Table 12</offsets></xref><offsets xml_i="28379" xml_f="28628" txt_i="20840" txt_f="21086">]. None of the patients in our study in either of the groups developed severe hypoglycemia (defined as blood glucose &lt;50 mg/dl and/or associated with come or seizure). No mortality was reported in either of the two groups during the study period.</offsets></p><table-wrap id="T12" position="float"><label><offsets xml_i="28677" xml_f="28685" txt_i="21087" txt_f="21095">Table 12</offsets></label><caption><p><offsets xml_i="28705" xml_f="28779" txt_i="21095" txt_f="21169">Comparison of parameters of safety between experimental and control groups</offsets></p></caption><graphic xlink:href="IJEM-21-836-g015"></graphic></table-wrap><p><offsets xml_i="28858" xml_f="28990" txt_i="21170" txt_f="21299">The event rate for severe hyperglycemia (defined as blood glucose &gt;300 mg/dl) was significantly lower in the experimental group [</offsets><xref ref-type="table" rid="T12"><offsets xml_i="29023" xml_f="29031" txt_i="21299" txt_f="21307">Table 12</offsets></xref><offsets xml_i="29038" xml_f="29130" txt_i="21307" txt_f="21399">]. No patients in either of the two groups developed diabetic ketoacidosis during the study.</offsets></p></sec></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="29192" xml_f="29193" txt_i="21402" txt_f="21403">D</offsets><sc><offsets xml_i="29197" xml_f="29206" txt_i="21403" txt_f="21412">ISCUSSION</offsets></sc></title><p><offsets xml_i="29222" xml_f="29530" txt_i="21413" txt_f="21721">There are a number of mechanisms by which glucocorticoids cause an increase of blood glucose. Glucocorticoids enhance the hepatic gluconeogenesis, and they cause an increase in the peripheral insulin resistance. They also cause degradation of proteins and lipids providing the substrate for gluconeogenesis.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="29563" xml_f="29564" txt_i="21721" txt_f="21722">9</offsets></xref><xref rid="ref10" ref-type="bibr"><offsets xml_i="29605" xml_f="29607" txt_i="21722" txt_f="21724">10</offsets></xref><offsets xml_i="29614" xml_f="29823" txt_i="21724" txt_f="21933">] The inhibition of peripheral glucose uptake by skeletal muscles is seen early after administration of glucocorticoids. This explains the reason that glucocorticoids cause initial postprandial hyperglycemia.[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="29857" xml_f="29859" txt_i="21933" txt_f="21935">11</offsets></xref><offsets xml_i="29866" xml_f="29867" txt_i="21935" txt_f="21936">]</offsets></p><p><offsets xml_i="29874" xml_f="30114" txt_i="21937" txt_f="22177">Existing literature on the topic of management of GCIH focuses on two major ideas. Studies on the glycemic effects of glucocorticoids show that in the initial period, glucocorticoids have a predominant effect on postprandial blood glucose.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="30148" xml_f="30150" txt_i="22177" txt_f="22179">12</offsets></xref><offsets xml_i="30157" xml_f="30383" txt_i="22179" txt_f="22405">] The first school of thought, to tackle GCIH, is increasing the premeal bolus insulin to counteract the postprandial surge of blood glucose. This is also the basis of the current guidelines proposed by the Endocrine Society.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="30416" xml_f="30417" txt_i="22405" txt_f="22406">5</offsets></xref><offsets xml_i="30424" xml_f="30596" txt_i="22406" txt_f="22578">] The use of this basal-bolus insulin approach for GCIH is well established, and there is evidence that it is superior to sliding-scale insulin which was used in the past.[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="30630" xml_f="30632" txt_i="22578" txt_f="22580">13</offsets></xref><offsets xml_i="30639" xml_f="30640" txt_i="22580" txt_f="22581">]</offsets></p><p><offsets xml_i="30647" xml_f="30715" txt_i="22582" txt_f="22650">An alternative approach was first proposed by Clore and Thurby-Hay.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="30749" xml_f="30751" txt_i="22650" txt_f="22652">14</offsets></xref><offsets xml_i="30758" xml_f="30789" txt_i="22652" txt_f="22683">] In a review article by Perez </offsets><italic><offsets xml_i="30797" xml_f="30802" txt_i="22683" txt_f="22688">et al</offsets></italic><offsets xml_i="30811" xml_f="30814" txt_i="22688" txt_f="22691">.,[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="30848" xml_f="30850" txt_i="22691" txt_f="22693">15</offsets></xref><offsets xml_i="30857" xml_f="31160" txt_i="22693" txt_f="22996">] a modified version of the above approach has been proposed for the management of GCIH. The basis of the second school of thought is that if we can give a specific insulin simultaneously with the glucocorticoid administration, we would be able to negate the hyperglycemic effect of the glucocorticoid.[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="31194" xml_f="31196" txt_i="22996" txt_f="22998">15</offsets></xref><offsets xml_i="31203" xml_f="31406" txt_i="22998" txt_f="23201">] The authors have proposed that the type of insulin we would use for neutralizing the glucocorticoid should have the same peaks and duration of action as the hyperglycemic effect of the glucocorticoid.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="31440" xml_f="31442" txt_i="23201" txt_f="23203">14</offsets></xref><offsets xml_i="31449" xml_f="31584" txt_i="23203" txt_f="23338">] A similar approach is followed by the Australian Diabetes Society guidelines for the management of hyperglycemia in indoor patients.[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="31618" xml_f="31620" txt_i="23338" txt_f="23340">16</offsets></xref><offsets xml_i="31627" xml_f="31686" txt_i="23340" txt_f="23399">] However, the evidence for the second approach is limited.</offsets></p><p><offsets xml_i="31693" xml_f="31714" txt_i="23400" txt_f="23421">Clore and Thurby-Hay[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="31748" xml_f="31750" txt_i="23421" txt_f="23423">14</offsets></xref><offsets xml_i="31757" xml_f="32172" txt_i="23423" txt_f="23838">] first recommended an alternative approach to the management of GCIH. They acknowledged the fact the glucocorticoids primarily increased postprandial blood glucose. However, they differed in the explanation to this phenomenon. It is often believed that the postprandial hyperglycemia seen in GCIH is due to the effect of morning glucocorticoids on the peripheral insulin sensitivity. However, Clore and Thurby-Hay[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="32206" xml_f="32208" txt_i="23838" txt_f="23840">14</offsets></xref><xref rid="ref17" ref-type="bibr"><offsets xml_i="32249" xml_f="32251" txt_i="23840" txt_f="23842">17</offsets></xref><offsets xml_i="32258" xml_f="32259" txt_i="23842" txt_f="23843">]</offsets></p><p><offsets xml_i="32266" xml_f="32289" txt_i="23844" txt_f="23867">The study done by Burt </offsets><italic><offsets xml_i="32297" xml_f="32302" txt_i="23867" txt_f="23872">et al</offsets></italic><offsets xml_i="32311" xml_f="32313" txt_i="23872" txt_f="23874">.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="32347" xml_f="32349" txt_i="23874" txt_f="23876">12</offsets></xref><offsets xml_i="32356" xml_f="32452" txt_i="23876" txt_f="23972">] later in 2011 provides evidence for their theory. The nondiabetic cohort in the study by Burt </offsets><italic><offsets xml_i="32460" xml_f="32465" txt_i="23972" txt_f="23977">et al</offsets></italic><offsets xml_i="32474" xml_f="32897" txt_i="23977" txt_f="24400">., who received glucocorticoids, developed a hyperglycemic peak after 6–8 h despite not having a significant postprandial glycemic surge. Their major recommendation which helped us shape our protocol was the use of insulin neutral protamine Hagedorn (NPH) along with prednisolone. They also recommended that the dose of the insulin NPH should be based on the dose of the prednisolone administered and weight of the patient.</offsets></p><p><offsets xml_i="32904" xml_f="33031" txt_i="24401" txt_f="24528">A number of guidelines recommend the use of NPH along with morning prednisolone. The guidelines by Australian Diabetes Society[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="33065" xml_f="33067" txt_i="24528" txt_f="24530">16</offsets></xref><offsets xml_i="33074" xml_f="33139" txt_i="24530" txt_f="24595">] and a recent guideline by the Joint British Diabetes societies[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="33173" xml_f="33175" txt_i="24595" txt_f="24597">18</offsets></xref><offsets xml_i="33182" xml_f="33264" txt_i="24597" txt_f="24679">] endorse similar protocols. Expert reviews on the topic also support the theory.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="33298" xml_f="33300" txt_i="24679" txt_f="24681">14</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="33341" xml_f="33343" txt_i="24681" txt_f="24683">15</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="33384" xml_f="33386" txt_i="24683" txt_f="24685">19</offsets></xref><xref rid="ref20" ref-type="bibr"><offsets xml_i="33427" xml_f="33429" txt_i="24685" txt_f="24687">20</offsets></xref><offsets xml_i="33436" xml_f="33530" txt_i="24687" txt_f="24781">] The Endocrine Society, however, does not endorse this protocol because of lack of evidence.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="33563" xml_f="33564" txt_i="24781" txt_f="24782">5</offsets></xref><offsets xml_i="33571" xml_f="33572" txt_i="24782" txt_f="24783">]</offsets></p><p><offsets xml_i="33579" xml_f="33741" txt_i="24784" txt_f="24946">As far as the glycemic profile of methylprednisolone is concerned, there is little reason to believe that it is any different from that of prednisolone. Seggelke </offsets><italic><offsets xml_i="33749" xml_f="33754" txt_i="24946" txt_f="24951">et al</offsets></italic><offsets xml_i="33763" xml_f="33765" txt_i="24951" txt_f="24953">.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="33798" xml_f="33799" txt_i="24953" txt_f="24954">4</offsets></xref><offsets xml_i="33806" xml_f="34008" txt_i="24954" txt_f="25156">] demonstrated the glycemic profile of morning dose of methylprednisolone in patients with cystic fibrosis. The pattern of glycemia was similar to what we have seen in the studies done for prednisolone.</offsets></p><p><offsets xml_i="34015" xml_f="34329" txt_i="25157" txt_f="25471">One of the unique aspects of our protocol is the use of insulin glargine along with insulin dexamethasone and use of regular human insulin along with hydrocortisone. Our recommendation comes from the studies which have shown the glycemic profile of dexamethasone and hydrocortisone as well as its pharmacokinetics.</offsets></p><p><offsets xml_i="34336" xml_f="34423" txt_i="25472" txt_f="25559">It is well known that dexamethasone has a longer half-life than other glucocorticoids.[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="34457" xml_f="34459" txt_i="25559" txt_f="25561">21</offsets></xref><offsets xml_i="34466" xml_f="34474" txt_i="25561" txt_f="25569">] Sethi </offsets><italic><offsets xml_i="34482" xml_f="34487" txt_i="25569" txt_f="25574">et al</offsets></italic><offsets xml_i="34496" xml_f="34498" txt_i="25574" txt_f="25576">.[</offsets><xref rid="ref22" ref-type="bibr"><offsets xml_i="34532" xml_f="34534" txt_i="25576" txt_f="25578">22</offsets></xref><offsets xml_i="34541" xml_f="34628" txt_i="25578" txt_f="25665">] demonstrated that the glycemic effect of dexamethasone starts in about 3 h. Eberhart </offsets><italic><offsets xml_i="34636" xml_f="34641" txt_i="25665" txt_f="25670">et al</offsets></italic><offsets xml_i="34650" xml_f="34652" txt_i="25670" txt_f="25672">.[</offsets><xref rid="ref23" ref-type="bibr"><offsets xml_i="34686" xml_f="34688" txt_i="25672" txt_f="25674">23</offsets></xref><offsets xml_i="34695" xml_f="34721" txt_i="25674" txt_f="25700">] and Lukins and Manninen[</offsets><xref rid="ref24" ref-type="bibr"><offsets xml_i="34755" xml_f="34757" txt_i="25700" txt_f="25702">24</offsets></xref><offsets xml_i="34764" xml_f="34918" txt_i="25702" txt_f="25856">] showed that glycemic peak due to dexamethasone is at around 9–10 h after administration. The glycemic effect of dexamethasone may last as long as 48 h.[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="34952" xml_f="34954" txt_i="25856" txt_f="25858">20</offsets></xref><offsets xml_i="34961" xml_f="35156" txt_i="25858" txt_f="26053">] Insulin glargine has a longer half-life and a longer duration of effect, and hence, it is a more suitable insulin to administer with the dexamethasone. This was the basis of our recommendation.</offsets></p><p><offsets xml_i="35163" xml_f="35250" txt_i="26054" txt_f="26141">Hydrocortisone has a much shorter half-life as compared to other glucocorticoids. Vila </offsets><italic><offsets xml_i="35258" xml_f="35263" txt_i="26141" txt_f="26146">et al</offsets></italic><offsets xml_i="35272" xml_f="35274" txt_i="26146" txt_f="26148">.[</offsets><xref rid="ref25" ref-type="bibr"><offsets xml_i="35308" xml_f="35310" txt_i="26148" txt_f="26150">25</offsets></xref><offsets xml_i="35317" xml_f="35534" txt_i="26150" txt_f="26367">] showed that hydrocortisone produced a glycemic peak 2 h after administration in healthy volunteers. Since regular human insulin has peak after 2 h, it is perfect insulin to be administered along with hydrocortisone.</offsets></p><p><offsets xml_i="35541" xml_f="35694" txt_i="26368" txt_f="26521">There are a few published studies which are similar to our study, which have studied and compared various protocols for the management of GCIH. Grommesh </offsets><italic><offsets xml_i="35702" xml_f="35707" txt_i="26521" txt_f="26526">et al</offsets></italic><offsets xml_i="35716" xml_f="35718" txt_i="26526" txt_f="26528">.[</offsets><xref rid="ref26" ref-type="bibr"><offsets xml_i="35752" xml_f="35754" txt_i="26528" txt_f="26530">26</offsets></xref><offsets xml_i="35761" xml_f="35859" txt_i="26530" txt_f="26628">] published a study for the management of GCIH in hospitalized patients. In the study by Grommesh </offsets><italic><offsets xml_i="35867" xml_f="35872" txt_i="26628" txt_f="26633">et al</offsets></italic><offsets xml_i="35881" xml_f="36053" txt_i="26633" txt_f="26805">., NPH was used irrespective of the type of glucocorticoid used, while in our study we used the “corrective insulin” depending on the type of glucocorticoid which was used.</offsets></p><p><offsets xml_i="36060" xml_f="36074" txt_i="26806" txt_f="26820">Ruiz de Adana </offsets><italic><offsets xml_i="36082" xml_f="36087" txt_i="26820" txt_f="26825">et al</offsets></italic><offsets xml_i="36096" xml_f="36098" txt_i="26825" txt_f="26827">.[</offsets><xref rid="ref27" ref-type="bibr"><offsets xml_i="36132" xml_f="36134" txt_i="26827" txt_f="26829">27</offsets></xref><offsets xml_i="36141" xml_f="36505" txt_i="26829" txt_f="27193">] published a clinical trial comparing insulin glargine versus insulin NPH as basal insulin in patients with GCIH. The protocol used in the experimental group differs from our study. In our study, we used insulin NPH along with prednisolone over and above the basal-bolus insulin (which included insulin glargine). However, in the study published by Ruiz de Adana </offsets><italic><offsets xml_i="36513" xml_f="36518" txt_i="27193" txt_f="27198">et al</offsets></italic><offsets xml_i="36527" xml_f="36530" txt_i="27198" txt_f="27201">.,[</offsets><xref rid="ref27" ref-type="bibr"><offsets xml_i="36564" xml_f="36566" txt_i="27201" txt_f="27203">27</offsets></xref><offsets xml_i="36573" xml_f="36666" txt_i="27203" txt_f="27296">] they have used insulin NPH three times a day before each meal along with the bolus insulin.</offsets></p><p><offsets xml_i="36673" xml_f="37553" txt_i="27297" txt_f="28177">Based on the results of our study, we suggest several recommendations for clinical practice. We recommend that all patients who receive glucocorticoids must have multiple blood glucose measurements for diagnosis of GCIH. We recommend the use of insulin NPH along with prednisolone and methylprednisolone, regular human insulin along with hydrocortisone, and insulin glargine along with dexamethasone as “correctional insulin.” The dose of correctional insulin should be based on the dose of the administered glucocorticoid and weight of the patient. For patients having preexisting diabetes mellitus given glucocorticoids, we recommend using correctional insulin over and above the background basal-bolus insulin regimen. For patients not having preexisting diabetes and developing GCIH, just the correctional insulin dose along with the administered glucocorticoid would suffice.</offsets></p><p><offsets xml_i="37560" xml_f="38153" txt_i="28178" txt_f="28771">Our study had several limitations. We proposed using specific insulin as “correctional insulin” for the management of hyperglycemia induced by dexamethasone and hydrocortisone, which was a unique part of our study. However, the number of patients enrolled in the study who received dexamethasone and hydrocortisone was too less to draw any conclusion based on a subgroup analysis. We did not collect data for the dose of insulin used in the experimental and control group. These data would have helped us understand whether there was a difference in insulin requirement between the two groups.</offsets></p><p><offsets xml_i="38160" xml_f="38669" txt_i="28772" txt_f="29281">Our study could be a primer for the future research on the field of GCIH. We propose dedicated scientific trials on the management of hyperglycemia secondary to dexamethasone, hydrocortisone, and other glucocorticoids. We also recommend that more studies should be conducted on the dysglycemic effects of systemic as well as other forms of glucocorticoids in both normal volunteers and hospitalized patients to understand the risk factors for GCIH and the glycemic patterns of the administered glucocorticoid.</offsets></p></sec><sec sec-type="conclusions" id="sec1-5"><title><offsets xml_i="38726" xml_f="38727" txt_i="29283" txt_f="29284">C</offsets><sc><offsets xml_i="38731" xml_f="38740" txt_i="29284" txt_f="29293">ONCLUSION</offsets></sc></title><p><offsets xml_i="38756" xml_f="39260" txt_i="29294" txt_f="29798">We developed a new protocol for the management of GCIH among hospitalized patients. The new protocol incorporated the use of “correctional insulin” matching the glycemic profile of the glucocorticoid administered to negate the effect of the glucocorticoid. When compared to the standard basal-bolus insulin protocol, the new protocol showed lower mean blood glucose and lower glycemic variability. The new protocol had lesser episodes of severe hyperglycemia, and the risk of hypoglycemia was negligible.</offsets></p><sec id="sec2-9"><title><offsets xml_i="39288" xml_f="39321" txt_i="29799" txt_f="29832">Financial support and sponsorship</offsets></title><p><offsets xml_i="39332" xml_f="39336" txt_i="29833" txt_f="29837">Nil.</offsets></p></sec><sec id="sec2-10" sec-type="COI-statement"><title><offsets xml_i="39396" xml_f="39417" txt_i="29839" txt_f="29860">Conflicts of interest</offsets></title><p><offsets xml_i="39428" xml_f="39463" txt_i="29861" txt_f="29896">There are no conflicts of interest.</offsets></p></sec></sec></body><back><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingle</surname><given-names>DJ</given-names></name></person-group><article-title>Production of glycosuria in normal rat by means of 17-hydroxy-11-dehydrocorticosterone</article-title><source>Endocrinology</source><year>1941</year><volume>29</volume><fpage>649</fpage><lpage>52</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donihi</surname><given-names>AC</given-names></name><name><surname>Raval</surname><given-names>D</given-names></name><name><surname>Saul</surname><given-names>M</given-names></name><name><surname>Korytkowski</surname><given-names>MT</given-names></name><name><surname>DeVita</surname><given-names>MA</given-names></name></person-group><article-title>Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients</article-title><source>Endocr Pract</source><year>2006</year><volume>12</volume><fpage>358</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">16901792</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Healy</surname><given-names>SJ</given-names></name><name><surname>Dungan</surname><given-names>KM</given-names></name></person-group><article-title>Hyperglycemia in patients with hematologic malignancies</article-title><source>Curr Diab Rep</source><year>2015</year><volume>15</volume><fpage>8</fpage><pub-id pub-id-type="pmid">25644817</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seggelke</surname><given-names>SA</given-names></name><name><surname>Gibbs</surname><given-names>J</given-names></name><name><surname>Draznin</surname><given-names>B</given-names></name></person-group><article-title>Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes</article-title><source>J Hosp Med</source><year>2011</year><volume>6</volume><fpage>175</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21387555</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umpierrez</surname><given-names>GE</given-names></name><name><surname>Hellman</surname><given-names>R</given-names></name><name><surname>Korytkowski</surname><given-names>MT</given-names></name><name><surname>Kosiborod</surname><given-names>M</given-names></name><name><surname>Maynard</surname><given-names>GA</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><etal></etal></person-group><article-title>Management of hyperglycemia in hospitalized patients in non-critical care setting: An endocrine society clinical practice guideline</article-title><source>J Clin Endocrinol Metab</source><year>2012</year><volume>97</volume><fpage>16</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">22223765</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haw</surname><given-names>JS</given-names></name><name><surname>Farrokhi</surname><given-names>F</given-names></name><name><surname>Smiley</surname><given-names>D</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Reyes</surname><given-names>D</given-names></name><name><surname>Newton</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Comparison of basal insulin regimens on glycemic variability in noncritically ill patients with type 2 diabetes</article-title><source>Endocr Pract</source><year>2015</year><volume>21</volume><fpage>1333</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">26307899</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Service</surname><given-names>FJ</given-names></name><name><surname>Molnar</surname><given-names>GD</given-names></name><name><surname>Rosevear</surname><given-names>JW</given-names></name><name><surname>Ackerman</surname><given-names>E</given-names></name><name><surname>Gatewood</surname><given-names>LC</given-names></name><name><surname>Taylor</surname><given-names>WF</given-names></name></person-group><article-title>Mean amplitude of glycemic excursions, a measure of diabetic instability</article-title><source>Diabetes</source><year>1970</year><volume>19</volume><fpage>644</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">5469118</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaff</surname><given-names>LJ</given-names></name><name><surname>Brazg</surname><given-names>R</given-names></name><name><surname>Hughes</surname><given-names>K</given-names></name><name><surname>Tideman</surname><given-names>AM</given-names></name><name><surname>Schachner</surname><given-names>HC</given-names></name><name><surname>Stenger</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Accuracy evaluation of contour next compared with five blood glucose monitoring systems across a wide range of blood glucose concentrations occurring in a clinical research setting</article-title><source>Diabetes Technol Ther</source><year>2015</year><volume>17</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">25260047</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>T</given-names></name><name><surname>McQueen</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Wang</surname><given-names>JC</given-names></name></person-group><article-title>Regulation of glucose homeostasis by glucocorticoids</article-title><source>Adv Exp Med Biol</source><year>2015</year><volume>872</volume><fpage>99</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">26215992</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Raalte</surname><given-names>DH</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name></person-group><article-title>Steroid diabetes: From mechanism to treatment?</article-title><source>Neth J Med</source><year>2014</year><volume>72</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24659588</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamez-Pérez</surname><given-names>HE</given-names></name><name><surname>Quintanilla-Flores</surname><given-names>DL</given-names></name><name><surname>Rodríguez-Gutiérrez</surname><given-names>R</given-names></name><name><surname>González-González</surname><given-names>JG</given-names></name><name><surname>Tamez-Peña</surname><given-names>AL</given-names></name></person-group><article-title>Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review</article-title><source>World J Diabetes</source><year>2015</year><volume>6</volume><fpage>1073</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26240704</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burt</surname><given-names>MG</given-names></name><name><surname>Roberts</surname><given-names>GW</given-names></name><name><surname>Aguilar-Loza</surname><given-names>NR</given-names></name><name><surname>Frith</surname><given-names>P</given-names></name><name><surname>Stranks</surname><given-names>SN</given-names></name></person-group><article-title>Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD</article-title><source>J Clin Endocrinol Metab</source><year>2011</year><volume>96</volume><fpage>1789</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">21411550</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosmanov</surname><given-names>AR</given-names></name><name><surname>Goorha</surname><given-names>S</given-names></name><name><surname>Stelts</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Umpierrez</surname><given-names>GE</given-names></name></person-group><article-title>Management of hyperglycemia in diabetic patients with hematologic malignancies during dexamethasone therapy</article-title><source>Endocr Pract</source><year>2013</year><volume>19</volume><fpage>231</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">23337144</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clore</surname><given-names>JN</given-names></name><name><surname>Thurby-Hay</surname><given-names>L</given-names></name></person-group><article-title>Glucocorticoid-induced hyperglycemia</article-title><source>Endocr Pract</source><year>2009</year><volume>15</volume><fpage>469</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">19454391</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez</surname><given-names>A</given-names></name><name><surname>Jansen-Chaparro</surname><given-names>S</given-names></name><name><surname>Saigi</surname><given-names>I</given-names></name><name><surname>Bernal-Lopez</surname><given-names>MR</given-names></name><name><surname>Miñambres</surname><given-names>I</given-names></name><name><surname>Gomez-Huelgas</surname><given-names>R</given-names></name></person-group><article-title>Glucocorticoid-induced hyperglycemia</article-title><source>J Diabetes</source><year>2014</year><volume>6</volume><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">24103089</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Chipps</surname><given-names>D</given-names></name><name><surname>Cornelius</surname><given-names>S</given-names></name><name><surname>Depczynski</surname><given-names>B</given-names></name><name><surname>Heels</surname><given-names>K</given-names></name><name><surname>O'Neal</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><etal></etal></person-group><source>ADS Guidelines for Routine Glucose Control In Hospital</source><year>2012</year><date-in-citation>Last accessed on 2016 Nov 10</date-in-citation><comment>Available from: <uri xlink:type="simple" xlink:href="https://www.diabetessociety.com.au/documents/ADSGuidelinesforRoutineGlucoseControlinHospitalFinal2012_000.pdf">https://www.diabetessociety.com.au/documents/ADSGuidelinesforRoutineGlucoseControlinHospitalFinal2012_000.pdf</uri></comment></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitzmiller</surname><given-names>JL</given-names></name><name><surname>Block</surname><given-names>JM</given-names></name><name><surname>Brown</surname><given-names>FM</given-names></name><name><surname>Catalano</surname><given-names>PM</given-names></name><name><surname>Conway</surname><given-names>DL</given-names></name><name><surname>Coustan</surname><given-names>DR</given-names></name><etal></etal></person-group><article-title>Managing preexisting diabetes for pregnancy: Summary of evidence and consensus recommendations for care</article-title><source>Diabetes Care</source><year>2008</year><volume>31</volume><fpage>1060</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">18445730</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>James</surname><given-names>J</given-names></name><name><surname>Dhatariya</surname><given-names>K</given-names></name></person-group><source>Management of Hyperglycaemia and Steroid (Glucocorticoid) Therapy</source><year>2014</year></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leahy</surname><given-names>JL</given-names></name></person-group><article-title>Insulin management of diabetic patients on general medical and surgical floors</article-title><source>Endocr Pract</source><year>2006</year><volume>12</volume><issue>Suppl 3</issue><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">16905523</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low Wang</surname><given-names>CC</given-names></name><name><surname>Draznin</surname><given-names>B</given-names></name></person-group><article-title>Practical approach to management of inpatient hyperglycemia in select patient populations</article-title><source>Hosp Pract</source><year>2013</year><volume>41</volume><fpage>45</fpage><lpage>53</lpage></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czock</surname><given-names>D</given-names></name><name><surname>Keller</surname><given-names>F</given-names></name><name><surname>Rasche</surname><given-names>FM</given-names></name><name><surname>Häussler</surname><given-names>U</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids</article-title><source>Clin Pharmacokinet</source><year>2005</year><volume>44</volume><fpage>61</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">15634032</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>R</given-names></name><name><surname>Naqash</surname><given-names>IA</given-names></name><name><surname>Bajwa</surname><given-names>SJ</given-names></name><name><surname>Dutta</surname><given-names>V</given-names></name><name><surname>Ramzan</surname><given-names>AU</given-names></name><name><surname>Zahoor</surname><given-names>SA</given-names></name></person-group><article-title>Evaluation of hyperglycaemic response to intra-operative dexamethasone administration in patients undergoing elective intracranial surgery: A randomised, prospective study</article-title><source>Asian J Neurosurg</source><year>2016</year><volume>11</volume><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">27057213</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberhart</surname><given-names>LH</given-names></name><name><surname>Graf</surname><given-names>J</given-names></name><name><surname>Morin</surname><given-names>AM</given-names></name><name><surname>Stief</surname><given-names>T</given-names></name><name><surname>Kalder</surname><given-names>M</given-names></name><name><surname>Lattermann</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Randomised controlled trial of the effect of oral premedication with dexamethasone on hyperglycaemic response to abdominal hysterectomy</article-title><source>Eur J Anaesthesiol</source><year>2011</year><volume>28</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">21192268</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukins</surname><given-names>MB</given-names></name><name><surname>Manninen</surname><given-names>PH</given-names></name></person-group><article-title>Hyperglycemia in patients administered dexamethasone for craniotomy</article-title><source>Anesth Analg</source><year>2005</year><volume>100</volume><fpage>1129</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15781533</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vila</surname><given-names>G</given-names></name><name><surname>Krebs</surname><given-names>M</given-names></name><name><surname>Riedl</surname><given-names>M</given-names></name><name><surname>Baumgartner-Parzer</surname><given-names>SM</given-names></name><name><surname>Clodi</surname><given-names>M</given-names></name><name><surname>Maier</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Acute effects of hydrocortisone on the metabolic response to a glucose load: Increase in the first-phase insulin secretion</article-title><source>Eur J Endocrinol</source><year>2010</year><volume>163</volume><fpage>225</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">20484150</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grommesh</surname><given-names>B</given-names></name><name><surname>Lausch</surname><given-names>MJ</given-names></name><name><surname>Vannelli</surname><given-names>AJ</given-names></name><name><surname>Mullen</surname><given-names>DM</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Richter</surname><given-names>SA</given-names></name><etal></etal></person-group><article-title>Hospital insulin protocol aims for glucose control in glucocorticoid-induced hyperglycemia</article-title><source>Endocr Pract</source><year>2016</year><volume>22</volume><fpage>180</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26492541</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruiz de Adana</surname><given-names>MS</given-names></name><name><surname>Colomo</surname><given-names>N</given-names></name><name><surname>Maldonado-Araque</surname><given-names>C</given-names></name><name><surname>Fontalba</surname><given-names>MI</given-names></name><name><surname>Linares</surname><given-names>F</given-names></name><name><surname>García-Torres</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease</article-title><source>Diabetes Res Clin Pract</source><year>2015</year><volume>110</volume><fpage>158</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">26474657</pub-id></element-citation></ref></ref-list></back></article>